Ceria Therapeutics announces operations expansion to Puerto Rico

Ceria Therapeutics, Inc. Awarded a $2,000,000 SBIR Grant to Advance Development of a Novel Treatment for Non-healing Diabetic Foot Ulcers

October 2023: Funding

Ceria Therapeutics, Inc. Awarded a $3,800,000 DoD Contract to Advance Development of a Novel Treatment for Acute Lung Injuries

September 2023: Funding

Ceria Therapeutics, Inc. Awarded a $2,100,000 SBIR Grant to Advance Development of a Novel Treatment for Acute Lung Injuries, Acute Lung Failure, and Acute Respiratory Distress Syndrome

Ceria Therapeutics, Inc. Awarded a $300,000 SBIR Grant to Advance Development of a Novel Treatment of Non-Healing Diabetic Foot Ulcers

Photopolymerized Zwitterionic Hydrogels with a Sustained Delivery of Cerium Oxide Nanoparticle-miR146a Conjugate Accelerate Diabetic Wound Healing

$8.6 million Advanced Industries Awards Accelerate 36 Colorado Start-ups:
Ceria Therapeutics, Inc. – Aurora, CO $250,000, CTx is developing a pipeline of drug products based on a single active agent to treat inflammatory diseases with severe morbidity such as nonhealing wounds, acute lung inflammation and severe intestinal distress. The company’s core technology addresses these conditions with single-administration drug products that block the underlying cause to rapidly resolve each condition. Patient benefits include the prevention of long-term drug therapy, surgery and even death.

Lung function improves after delayed treatment with CNP-miR146a following acute lung injury

Cerium oxide nanoparticle conjugation to microRNA-146a mechanism of correction for impaired diabetic wound healing

Cerium oxide nanoparticle delivery of microRNA-146a for local treatment of acute lung injury

Nanosilk Increases the Strength of Diabetic Skin and Delivers CNP-miR146a to Improve Wound Healing

PRE-IND feedback received from FDA for COVID-19 positive ARDS indication

FDA grants CTAP (Coronavirus Treatment Acceleration Program) designation for COVID-19 Positive ARDS Pre-IND

Early Investment by Children’s Hospital CO

Injectable, self-healable zwitterionic cryogels with sustained microRNA – cerium oxide nanoparticle release promote accelerated wound healing

Ceria Therapeutics was founded

FDA feedback on DFU pre-IND

Use of Cerium Oxide Nanoparticles Conjugated with MicroRNA-146a to Correct the Diabetic Wound Healing Impairment